FABHALTA Drug Patent Profile

Which patents cover Fabhalta, and when can generic versions of Fabhalta launch?

Fabhalta is a drug marketed by Novartis and is included in one NDA. There are eight patents protecting this drug.

The generic ingredient in FABHALTA is iptacopan hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the iptacopan hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Fabhalta

Fabhalta will be eligible for patent challenges on December 5, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 25, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FABHALTA

US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	3,544
Drug Prices:	Drug price information for FABHALTA
What excipients (inactive ingredients) are in FABHALTA?	FABHALTA excipients list
DailyMed Link:	FABHALTA at DailyMed

See drug prices for FABHALTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FABHALTA

Constraining patent/regulatory exclusivity:

11,603,363

NDA:

218276

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for FABHALTA

Drug Class	Complement Factor B Inhibitor
Mechanism of Action	Complement Factor B Inhibitors

US Patents and Regulatory Information for FABHALTA

FABHALTA is protected by ten US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,603,363.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes	12,285,422
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes	11,723,901
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes	12,384,758

International Patents for FABHALTA

When does loss-of-exclusivity occur for FABHALTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Israel

Japan

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FABHALTA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	096904
Argentina	132461
Australia	2014290298

Supplementary Protection Certificates for FABHALTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3022192	301292	Netherlands		PRODUCT NAME: IPTACOPAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1802 20240521
3022192	CA 2024 00035	Denmark		PRODUCT NAME: IPTACOPAN; REG. NO/DATE: EU/1/24/1802 20240521
3022192	LUC00358	Luxembourg		PRODUCT NAME: IPTACOPAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/24/1802 20240521

FABHALTA (rilzabrutinib) market dynamics and financial trajectory: exclusivity timeline, payer and channel position, and generic/biosimilar risk

Last updated: July 28, 2026

FABHALTA is the brand name for rilzabrutinib, a BTK inhibitor approved for dermatomyositis-related indications and marketed in a category where near-term growth is driven by (1) label expansion, (2) payer uptake dynamics for oral small molecules, and (3) sequencing versus competing systemic immunomodulators. Revenue trajectory and market share will be constrained by the strength and timing of patent exclusivity and by the speed of competitive entries, including potential BTK-class rivals and any near-term generic/biosimilar-like threats (typically in oral small molecules only if patents fall and Orange Book exclusivity permits).

What is FABHALTA (rilzabrutinib) and what market does it target?

Answer: FABHALTA (rilzabrutinib) targets autoimmune/dermatomyositis indications as an oral BTK inhibitor, competing against systemic immunosuppressants and other targeted immune-modulating therapies.

What competitors define the TAM in dermatomyositis and related autoimmune skin muscle disease?

Key commercial dynamics for rilzabrutinib are set by:

• Line of therapy: entry after inadequate response to steroids and conventional immunosuppressants generally supports higher pricing power if efficacy and tolerability are strong.
• Oral convenience vs infusion biologics: BTK inhibitors are positioned against infusion-based biologics and high-burden regimens.
• Steroid-sparing expectations: payers prefer products that reduce glucocorticoid dose and associated medical cost.

How does dosing form and administration affect payer coverage?

As an oral therapy, FABHALTA avoids infusion-site and administration costs, which typically improves formulary acceptance versus biologics. Coverage is still governed by:

• step edits and prior authorization
• evidence standards for disease activity and failure of conventional therapy
• budget impact thresholds at managed care organizations

How strong are FABHALTA’s exclusivity and patent protections that shape financial trajectory?

Answer: Financial trajectory is determined by when patent term expires and whether Orange Book-listed patents or exclusivity prevent generic competition. For oral small molecules, generic entry timing is usually the primary inflection point.

What patents protect rilzabrutinib and its lifecycle?

The controlling risks to future revenue are:

• Composition-of-matter patents covering the core molecule.
• Formulation and polymorph patents covering specific solid-state forms, excipients, or manufacturing-related parameters.
• Method-of-use patents tied to the dermatomyositis indication and measured endpoints.
• Regulatory exclusivity (if applicable): new chemical entity or new clinical investigation exclusivity blocks generic approval routes for defined periods.

When does FABHALTA lose exclusivity?

Answer: Loss of exclusivity is governed by the last-expiring Orange Book patent and any statutory exclusivity. Once the last barrier is cleared, generic or authorized competitors can pursue FDA approval (typically via Abbreviated New Drug Application for small molecules).

What is the Orange Book status of FABHALTA?

Answer: Orange Book status determines:

• whether patents are listed for the reference product and listed claims
• which patent numbers could be attacked via Paragraph IV
• whether exclusivity blocks approval even if a generic challenges a listed patent

What generic entry risks exist for FABHALTA?

Answer: The generic entry risk is concentrated in the patent expiry window. For oral small molecules, the typical play is Paragraph IV (Section 505(j)), followed by settlement or litigation that can delay launch.

What Paragraph IV challenges are likely in a BTK inhibitor class?

Commercially relevant scenarios:

• Launch after first permitted date if a court decides invalidity/non-infringement or settlement allows earlier entry.
• Delayed launch if patents remain enforceable or if the FDA approves only after exclusivity and unchallenged patents expire.
• Design-around risk is lower than with biologics but exists with formulation or manufacturing patents.

What settlement dynamics govern timing?

Revenue impact usually tracks:

• the “180-day exclusivity” incentive for the first Paragraph IV filer
• shared launch dates in settlements
• court injunction scope and stay orders

How does FABHALTA compare with other dermatomyositis therapies on market positioning?

Answer: Market positioning usually comes down to payer-funding willingness to move members off steroids and conventional immunosuppressants, balanced against safety monitoring and adverse event management.

How does FABHALTA compare with systemic immunosuppressants and targeted options?

Key commercial comparisons:

• Efficacy durability (response rates at fixed timepoints and sustained improvements)
• Safety (infection risk, lab monitoring, bruising or bleeding tendencies typical of BTK-class drugs)
• Tolerability and adherence (oral adherence and discontinuation rates)

What does “switching” look like in claims data?

In practice, adoption curves typically show:

• early uptake among patients who are already eligible based on guideline disease severity
• later expansion to broader real-world populations via formulary changes, copay support, or step-therapy loosening

What payer and channel dynamics will determine FABHALTA’s sales growth?

Answer: Growth depends on managed care uptake, pharmacy benefit design, and specialty channel leverage, not just clinical outcomes.

Specialty pharmacy and formulary placement

For an oral immunology therapy:

• preferred status at large PBMs can materially change net pricing
• utilization management (prior authorization, quantity limits) can slow early penetration
• patient support programs can reduce net copays and improve persistence

Net revenue drivers that matter for the financial trajectory

Commercial finance typically tracks:

• list price vs net price (rebates, commercial discounts)
• channel mix (hospital outpatient vs retail specialty vs mail)
• persistence and dose modification after safety events

What is the financial trajectory outlook for FABHALTA?

Answer: Without confirmed, product-specific audited financials and sales reporting, the forward trajectory can only be characterized by the standard market mechanics for oral immunology drugs: adoption, label expansion, and exclusivity duration dictate the ceiling; the generic entry date dictates the time-to-decline.

What usually drives year-over-year revenue acceleration?

• new patient starts from guideline alignment and improved payer coverage
• geographic rollout intensity (US first then ex-US, depending on approvals)
• expanding label scope if approved post-initial launch
• improved persistence driven by tolerability and stable safety management

What usually drives revenue deceleration?

• tighter utilization management after budget impact review
• increased discounting to defend formulary placement
• competitive launches in the BTK inhibitor or immunology space

What role does litigation play in FABHALTA’s commercial timetable?

Answer: Patent litigation and settlements determine whether generic entry is delayed or accelerated relative to the statutory expiry timeline.

What litigation outcomes change revenue risk?

• invalidity or non-infringement decisions that remove key Orange Book barriers
• consent judgments or stipulations that narrow injunction scope
• settlements that define launch timing and design-around boundaries

Where does risk concentrate?

Commercially, the highest leverage events are:

• court rulings that eliminate the last remaining composition-of-matter or method-of-use barrier
• FDA approvals that become possible only after a particular patent is cleared

How does FABHALTA’s risk profile compare with other targeted immunology brands?

Answer: The risk profile is similar to other oral targeted immunology assets: steady revenue early if uptake is strong, then a patent-expiry cliff if exclusivity is narrow or litigation reduces barriers.

Key differences that affect outcome

• molecule-specific patent coverage depth (composition and formulation)
• enforceability history in the jurisdiction
• whether label expansions add new patent thickets or accelerate generic attack relevance

Key timeline mechanics: what to monitor for FABHALTA’s next financial inflection

Answer: Track three calendars: (1) regulatory and label milestones, (2) patent term and exclusivity expiry, (3) Paragraph IV/settlement milestones.

Commercial milestone calendar

• FDA label expansions: add new cohorts and increase addressable population.
• Payer policy changes: can cause stepwise utilization lifts or drops.
• Patent expiry and Orange Book changes: determine the feasibility of generic entry.
• Litigation/settlement dates: define exact launch timing.

Key Takeaways

• FABHALTA’s revenue trajectory is primarily shaped by managed care adoption, persistence, and any label expansion that broadens eligible patients.
• Patent and Orange Book status determine the timing of potential generic competition, which is the dominant factor in revenue decline risk for oral small molecules.
• Paragraph IV challenges and settlements are the main litigation channels that can accelerate or delay generic entry.
• Near-term sales depend on formulary placement, prior authorization dynamics, and net price erosion from competitive pressure.

FAQs

1) What determines whether FABHALTA will be preferred on formulary for dermatomyositis?
Formulary status is typically driven by prior authorization criteria, step edits, net price competitiveness, and evidence of steroid-sparing or clinically meaningful outcomes versus comparators.

2) How does Orange Book patent listing affect when generics can launch FABHALTA?
Orange Book listings define the legal barriers a generic must address through Paragraph IV. Launch depends on the last unexpired barrier and whether litigation or settlement removes it.

3) What are the most common causes of early treatment discontinuation for oral BTK inhibitors like rilzabrutinib?
Adverse events and infection risk management, lab abnormalities requiring monitoring, and intolerance-related discontinuation are typical drivers in real-world adoption curves.

4) What is the impact of net pricing and rebates on FABHALTA’s reported revenue growth?
Net revenue reflects list price less rebates and discounts. Aggressive contracting can support volume but compress net pricing, smoothing or reversing apparent growth.

5) How do label expansions change the addressable market for FABHALTA?
They expand the eligible patient population and can shift formulary positioning from restricted use to broader coverage, increasing both starts and persistence.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Patent and Trademark Office. (n.d.). Patent Public Search. USPTO. https://ppubs.uspto.gov/
4. FDA. (n.d.). Guidance for Industry: Patent Listing Requirements and Changes to Approved NDA/ANDA. FDA. https://www.fda.gov/

DrugChatter Q&A for FABHALTA

Fabhalta igan approval?
Fabhalta price?